Intra-Cellular Therapies (ITCI) Tops Q3 EPS by 6c

Intra-Cellular Therapies (NASDAQ: ITCI) reported Q3 EPS of ($0.22), $0.06 better than the analyst estimate of ($0.28).

For earnings history and earnings-related data on Intra-Cellular Therapies (ITCI) click here.

You May Also Be Interested In

• Kodiak Gas Services, Inc. (KGS) Reports Q2 EPS of $0.55
• iRhythm Technologies (IRTC) Tops Q2 EPS by 63c; Offers Guidance
• HCI Group (HCI) Tops Q2 EPS by 55c